FMO5 Inhibitors

Chemical inhibitors of FMO5 include a range of compounds that disrupt its enzymatic function through interaction with its flavin adenine dinucleotide (FAD) cofactor or active site. Methimazole operates as a substrate analogue, directly competing with natural substrates of FMO5, which prevents the enzyme from catalyzing its typical reactions. Tranylcypromine's mechanism involves irreversible binding to the FAD cofactor, without which FMO5 cannot function. This binding renders FMO5 inactive by blocking the essential cofactor from participating in the enzymatic process. Benzydamine and methylene blue also inhibit FMO5 by interacting with the FAD cofactor. They act as competitive inhibitors, preventing the binding of FAD to the enzyme, which is necessary for the enzyme to carry out its normal metabolic functions.

Other chemicals such as ketoconazole and chlorpromazine inhibit FMO5 by potentially altering its FAD binding or reducing its enzymatic activity. Their structures allow them to interact with flavin-containing enzymes, and their binding can change the conformation of FMO5, leading to decreased activity. Furafylline, thiabendazole, and biperiden inhibit FMO5 by binding to the enzyme's active site, which physically blocks substrates from accessing the site necessary for their metabolism. Ticlopidine forms a reactive metabolite that binds covalently to FAD, which again inhibits the FMO5 enzyme by depriving it of its required cofactor. Cimetidine and quinacrine can inhibit FMO5 by a similar mechanism, interfering with the FAD-dependent enzymatic activity, thereby inhibiting the normal functioning of FMO5. Each chemical's interaction with FMO5, whether through the active site blockade or FAD cofactor interaction, leads to a decrease in the enzyme's overall activity within the cell.